Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: In-vivo antihyperglycemic activities and blood pressure lowering studies

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7883-7891

  Kaur, Jatinder ^a   Bhardwaj, Atul ^a   Huang, Zhangjian ^a   Narang, Deepak ^a   Chen, Ting Yueh ^a   Plane, Frances ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[[4 [2 (5 CHLORO 2 METHOXYBENZAMIDO)ETHYL]BENZOYL]OXY]METHOXY] 3,3 DIETHYLTRIAZ 1 ENE 2 OXIDE; 2 [[[4 [2 (5 CHLORO 2 METHOXYBENZAMIDO)ETHYL]BENZOYL]OXY]METHOXY] 1 (PYRROLIDIN 1 YL)DIAZENE OXIDE; 2 NITROOXYETHYL (4 ISOPROPYLCYCLOHEXANECARBOXAMIDO) 3 PHENYLPROPANOATE; 3 BENZYL 10 ETHYL (4 ISOPROPYLCYCLOHEXYL) 1,4 DIOXO 5,7 DIOXA 2,8,9,10 TETRAAZADODEC 8 EN 9 OXIDE; ANTIDIABETIC AGENT; GLUCOSE; MEGLITINIDE; NATEGLINIDE; NITRIC OXIDE; PHOSPHATE BUFFERED SALINE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; MALE; NONHUMAN; PH; RAT; SERUM; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

BENZAMIDES; BLOOD PRESSURE; CYCLOHEXANES; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; NITRIC OXIDE; PHENYLALANINE; PRODRUGS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84866316660     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300997w     Document Type: Article

References (40)

1. Virsaladze, D.; Kipiani, V. Endothelial dysfunction in diabetic vasculopathy Ann. Biochem. Res. Educ. 2001, 1, 44-48
2. Cooper, M. E.; Bonnet, F.; Oldfield, M.; Jandeleit-Dahm, K. Mechanisms of diabetic vasculopathy: An overview Am. J. Hypertens. 2001, 14, 475-486 (Pubitemid 32417606)
3. Clark, C. M.; Lee, D. A. Prevention and treatment of the complications of Diabetes Mellitus N. Engl. J. Med. 1995, 332, 1210-1217
4. Rahman, S.; Rahman, T.; Ismail, A. A.; Rashid, A. R. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis Diabetes Obes. Metab. 2007, 9, 767-780 (Pubitemid 47555200)
5. Desouza, C. V.; Bolli, G. B.; Fonseca, V. Hypoglycemia, diabetes, and cardiovascular events Diabetes Care 2010, 33, 1389-1394
6. Prolisso, G.; D'Amore, A.; Balbi, V.; Volpe, C.; Galzerano, D.; Giugliano, D.; Sgambato, S.; Varricchio, M.; D'Onofrio, F. Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics Am. J. Physiol. 1994, 266, E261-E268
7. Ogihara, T.; Rakugi, H.; Ikegami, H.; Mikami, H.; Masuo, K. Enhancement of insulin sensitivity by Troglitazone lowers blood pressure in diabetic hypertensives Am. J. Hypertens. 1995, 8, 316-320
8. Torlone, E.; Rambotti, A. M.; Perriello, G.; Botta, G.; Santeusanio, F.; Brunetti, P.; Bolli, G. B. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension Diabetologia 1991, 34, 119-125
9. Grundy, S. M.; Benjamin, I. J.; Burke, G. L.; Chait, A.; Eckel, R. H.; Howard, B. V.; Mitch, W.; Smith, S. C.; Sowers, J. R. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association Circulation 1999, 100, 1134-1146 (Pubitemid 29416243)
10. Becker, A.; Bosb, G.; de Vegt, F.; Kostense, P. J.; Dekker, J. M.; Nijpels, G.; Heinea, R. J.; Bouter, L. M.; Stehouwer, C. D. A. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease Eur. Heart J. 2003, 24, 1406-1413 (Pubitemid 36961830)
11. Bhattacharyya, O. K.; Shah, B. R.; Booth, G. L. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines CMAJ 2008, 179, 920-926
12. Mazzone, T.; Chait, A.; Plutzky, J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies Lancet 2008, 371, 1800-1809 (Pubitemid 351697956)
13. Drexler, H.; Hornig, B. Endothelial dysfunction in human disease J. Mol. Cell. Cardiol. 1999, 31, 51-60 (Pubitemid 29078218)
14. Storey, A. M.; Perry, C. J.; Petrie, J. R. Endothelial dysfunction in type 2 diabetes Br. J. Diabetes Vasc. Dis. 2001, 1, 22-27
15. Scheen, A. J. Treatment of type 2 diabetes Acta Clin. Belg. 2003, 58, 318-324 (Pubitemid 38017321)
16. Calderone, V.; Rapposelli, S.; Martelli, A.; Digiacomo, M.; Testai, L.; Torri, S.; Marchetti, P.; Breschi, M. C.; Balsamo, A. NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs Bioorg. Med. Chem. 2009, 17, 5426-5432
17. Tamboli, Y.; Lazzarato, L.; Marini, E.; Guglielmo, S.; Novelli, M.; Beffy, P.; Masiello, P.; Fruttero, R.; Gasco, A. Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues Bioorg. Med. Chem. Lett. 2012, 22, 3810-3815
18. Butler, A. R.; Williams, D. L. H. The physiological role of nitric oxide Chem. Soc. Rev. 1993, 22, 233-241
19. For an excellent perspective, see Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543 and references cited therein. (Pubitemid 41504710)
20. Edwards, I. R.; Aronson, J. K. Adverse drug reactions: Definitions, diagnosis and management Lancet 2000, 356, 1255-1259
21. Kokil, G. R.; Rewatkar, P. V.; Verma, A.; Thareja, S.; Naik, S. R. Pharmacology and chemistry of diabetes mellitus and antidiabetic drugs: A critical review Curr. Med. Chem. 2010, 17, 4405-4423
22. Shinkai, H. Recent developments in oral hypoglycemic agents Drug Discovery Today 1999, 4, 283-288 (Pubitemid 29317331)
23. Shinkai, H. Novel antidiabetic agents Exp. Opin. Ther. Patents 2000, 10, 59-66 (Pubitemid 30009170)
24. Shinkai, H.; Nishikawa, M.; Sato, Y.; Toi, K.; Kumashiro, I.; Seto, Y.; Fukuma, M.; Dan, K.; Toyoshima, S. N-(Cyclohexylcarbony1)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents J. Med. Chem. 1989, 32, 1436-1441 (Pubitemid 19205345)
25. Hasan, R.; Suresh, D. K.; Sheth, H.; Khalid, M. S.; Mohiuddin, M. A Study on drug-drug interaction of diltiazem with nateglinide in diabetic animals RJPS 2011, 1, 123-126
26. Brown, G. R; Foubister, A. J. Receptor binding sites of hypoglycemic sulfonylureas and related [ (acylamino)alkyl]benzoic acids J. Med. Chem. 1984, 27, 79-81 (Pubitemid 14176382)
27. Ribes, G.; Trimble, E. R.; Blayac, J. P.; Wollheim, C. B.; Puech, R.; Loubatieres- Mariani, M. S. Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog Diabetologia 1981, 20, 501-505 (Pubitemid 11098923)
28. Tang, X.; Xian, M.; Trikha, M.; Honn, K. V.; Wang, P. G. Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents Tetrahedron Lett. 2001, 42, 2625-2629 (Pubitemid 32245515)
29. Abdellatif, K. R. A.; Dong, Y.; Chen, Q.-H.; Chowdhury, M. A.; Knaus, E. E. Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: Design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies Bioorg. Med. Chem. 2007, 15, 6796-6801 (Pubitemid 47385238)
30. Ramkrishnana, A.; Kapkoti, G. S.; Dehury, S. K. A Process for the Preparation of N-{[ trans -4-(1-Methylethyl)cyclohexyl]carbonyl}- D -phenylalanine. WO2010/106550 A2, 2010.
31. Gschwend, H. W.; Hamadan, A. Synthetic approaches to 9-chloro-7-(o- fluorophenyl)-5H-dibenz[c, e]azepine J. Org. Chem. 1982, 47, 3652-3657
32. 2N[N(O)NO]- O -functionalization chemistry J. Org. Chem. 1992, 57, 6134-6138
33. Hrabie, J. A.; Klose, J. R. New nitric oxide-releasing zwitterions derived from polyamines J. Org. Chem. 1993, 58, 1472-1476
34. Velazquez, C.; Rao, P. N. P.; Knaus, E. E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evaluation, and nitric oxide release studies J. Med. Chem. 2005, 48, 4061-4067 (Pubitemid 40800614)
35. Garthwaite, J; Southam, E.; Boulton, C. L.; Nielsen, E. B.; Schmidt, K.; Mayer, B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Mol. Pharmacol. 1995, 48, 184-188
36. Saavedra, J. E.; Billiar, T. R.; Williams, D. L.; Kim, Y.; Watkins, S. C.; Keefer, L. K. Targeting nitric oxide (NO) in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor- α -induced apoptosis and toxicity in the liver J. Med. Chem. 1997, 40, 1947-1954 (Pubitemid 27265970)
37. Drago, R. S.; Karstetter, B. R. The reactions of nitrogen (II) oxide with various primary and secondary amines J. Am. Chem. Soc. 1961, 83, 1819-1822
38. Bhardwaj, A.; Batchu, S. N.; Kaur, J.; Huang, Z.; Seubert, J. M.; Knaus, E. E. Cardiovascular properties of a nitric oxide releasing rofecoxib analogue: Beneficial anti-hypertensive activity and enhanced recovery in an ischemic reperfusion injury model ChemMedChem 2012, 7, 1365-1368
39. Cocco, M. T.; Congiu, C.; Onnis, V.; Morelli, M.; Cauli, O. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties Eur. J. Med. Chem. 2003, 38, 513-518 (Pubitemid 36588917)
40. Plane, F.; Sampson, L. J.; Smith, J. J.; Garland, C. J. Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: variable role for smooth muscle hyperpolarization Br. J. Pharmacol. 2001, 133, 665-672 (Pubitemid 32642872)